Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xieran Li

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
BMC Medical Research Methodology|November 6, 2020
Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpointXieran Li, Carolin Herrmann, Geraldine Rauch
BMC Medical Research Methodology|November 26, 2020
Correction to: Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpointXieran Li, Carolin Herrmann, Geraldine Rauch
BMC Medical Research Methodology|March 28, 2024
Optimal futility stopping boundaries for binary endpointsMichaela Maria Freitag, Xieran Li, Geraldine Rauch
Drug Metabolism and Pharmacokinetics|July 23, 2023
Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantationXieran Li, Krzysztof Kalwak, Rita Beier, et al.
Bone Marrow Transplantation|November 5, 2024
Real world outcome analysis of treosulfan-based conditioning prior to allo-HCT in patients with MDS compared to clinical trial dataMatthias Stelljes, Katja Sockel, Matthias Floeth, et al.
British Journal of Clinical Pharmacology|November 20, 2024
Impact of treosulfan exposure on clinical outcome after allogeneic stem cell transplantation in children: A substudy of 2 phase 2 trialsKrzysztof Kalwak, Ajay Vora, Peter Bader, et al.
Bone Marrow Transplantation|November 5, 2023
Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trialKarl-Walter Sykora, Rita Beier, Ansgar Schulz, et al.
Haematologica|January 29, 2026
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trialFriedrich Stölzel, Matthias Stelljes, Dietrich Wilhelm Beelen, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
BMC Medical Research Methodology|November 6, 2020
Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpointXieran Li, Carolin Herrmann, Geraldine Rauch
BMC Medical Research Methodology|November 26, 2020
Correction to: Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpointXieran Li, Carolin Herrmann, Geraldine Rauch
BMC Medical Research Methodology|March 28, 2024
Optimal futility stopping boundaries for binary endpointsMichaela Maria Freitag, Xieran Li, Geraldine Rauch
Drug Metabolism and Pharmacokinetics|July 23, 2023
Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantationXieran Li, Krzysztof Kalwak, Rita Beier, et al.
Bone Marrow Transplantation|November 5, 2024
Real world outcome analysis of treosulfan-based conditioning prior to allo-HCT in patients with MDS compared to clinical trial dataMatthias Stelljes, Katja Sockel, Matthias Floeth, et al.
British Journal of Clinical Pharmacology|November 20, 2024
Impact of treosulfan exposure on clinical outcome after allogeneic stem cell transplantation in children: A substudy of 2 phase 2 trialsKrzysztof Kalwak, Ajay Vora, Peter Bader, et al.
Bone Marrow Transplantation|November 5, 2023
Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trialKarl-Walter Sykora, Rita Beier, Ansgar Schulz, et al.
Haematologica|January 29, 2026
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trialFriedrich Stölzel, Matthias Stelljes, Dietrich Wilhelm Beelen, et al.
Pageof 1